# Patent Watch: NUS Targets Cannabinoid Biosynthesis With

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-nus-targets-cannabinoid-biosynth-2026-10-09/
> **Published:** 2026-10-09T23:28:00-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T23:28:00-04:00
> **Clinical Summary:** The application identifies novel cannabinoid synthases for producing cannabinoids from cannabigerolic acid (CBGA), a precursor in cannabinoid biosynthesis.

---

PATENT WATCH
 US20260234574A1
 
 

# Patent Watch: NUS Targets Cannabinoid Biosynthesis With Novel Synthases

 
 **Assignee:** National University of Singapore
 **Inventors:** Maybelle Darlene Kho Go, Wen Shan Yew
 **Published:** 2026-08-13
 
 

 
 Invention Summary & Claims
 

The application identifies novel cannabinoid synthases for producing cannabinoids from cannabigerolic acid (CBGA), a precursor in cannabinoid biosynthesis. This is a manufacturing approach rather than a finished drug formulation or delivery system: the enzymes function as production catalysts, while resulting cannabinoids could become active pharmaceutical ingredients after appropriate qualification. Specific enzyme designs, product profiles, yields, excipients, and administration routes cannot be established from the available disclosure details.

 

 

## Clinical Perspective & Therapeutic Significance

 

If successfully developed, this approach could support more consistent cannabinoid production and potentially improve access to compounds that are difficult to obtain through plant extraction. Biosynthesis alone does not establish improved bioavailability, greater safety, or efficacy for any clinical indication. Patient benefit would depend on product identity, purity, formulation, dosing, and clinical validation.

 

## Intellectual Property & Market Landscape

 

National University of Singapore is identified as the applicant, positioning this application as university-origin biotechnology intellectual property. Unlike conventional [cannabis products](https://cedclinic.com/cbd-gummies-daily-use-evidence-men/) manufactured through cultivation and extraction, the proposed approach centers on enzyme-mediated cannabinoid production. Its competitive value would depend on demonstrated enzyme performance, manufacturing costs, scalability, and the scope of any granted claims.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260234574A1)](https://patents.google.com/patent/US20260234574A1/en).
 

 
 Editorial Commentary
 

The application deserves attention as a potential production innovation, not as evidence of a new treatment. Its clinical relevance will depend on whether the technology produces well-characterized cannabinoids that can be developed into reliable, evidence-based medicines.

 

 
 

### Frequently Asked Questions

 
 Are biosynthesized cannabinoids safer or more effective than plant-derived cannabinoids?
 Not inherently. When molecular identity and purity are equivalent, differences in clinical performance depend more on formulation, dose, impurities, and supporting evidence than on the production source alone.

 Does this patent application mean the technology has passed clinical trials?
 No. A published patent application describes intellectual property claims, not regulatory approval or proven clinical efficacy, and the available disclosure details do not establish clinical trial results.

 When could patients access medicines made using these cannabinoid synthases?
 No reliable availability timeline can be established from the application details. A resulting medicine would require validated manufacturing, appropriate safety and efficacy evidence, and applicable regulatory authorization before routine clinical use.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).